Hemophilia Federation of America is a national nonprofit organization that assists, educates, and advocates for the bleeding disorders community.
The following is an excerpt from a statement from Genentech. Read the entire statement HERE. _________________________________________________________ Genentech has recently learned that a patient in the Phase III HAVEN 2 clinical trial developed a neutralizing anti-drug antibody. For this patient, the anti-drug antibody resulted in reduced efficacy of HEMLIBRA.
Sign up for E-mails, Dateline Magazine, and other ways to stay connected.